With an eye on an "emergent global health concern," GeneOne Life Science teamed up with the Walter Reed Army Institute of Research this week to usher its vaccine for Middle East respiratory syndrome (MERS) into a first-in-human trial at the institute.
Louis Schofield, director of the Australian Institute of Tropical Health and Medicine at James Cook University, received a grant from the Bill & Melinda Gates Foundation worth AU$2.8 million to pursue preclinical development of a malaria vaccine.
As Wall Street vacillates on the whole biotech sector, each week becomes an unwitting referendum on just how long the IPO window for drug developers might stay open. Voyager Therapeutics and Wave Life Sciences, raising a combined $172 million this week, demonstrated that biotech's years-long boom on the public markets is not quite through.
This week at the World Vaccines Congress in Spain, Sanofi Pasteur announced that in collaboration with the University of Georgia it has developed a candidate flu vaccine through genetic sequencing of many flu viruses. The vaccine, dubbed Cobra, is designed to protect against multiple strains over several years using common sequences the strains share.
As scientists search for lighter, low-cost alternatives to traditional imaging tools such as MRI or CT scans, engineers at Stanford University are developing a device that uses microwaves and ultrasound to pinpoint targets without touch, potentially improving tumor detection.
Some of the old San Diego gang that brought you Lumena--bought out by Shire last year--have moved into top positions at Amplyx Pharmaceuticals as the biotech heads in a new direction, pointing a recently in-licensed antifungal product toward the clinic with $40.5 million from a high-profile group of venture players.
The race is on to develop U.S. sources for a material necessary to create the most widely used radioisotope in medical diagnostic imaging. Now GE Healthcare and startup Shine Technologies have disclosed that they have successfully used GE's existing tech to create the common medical radioisotope technetium-99m (Tc‑99m) from molybdenum-99 (Mo-99) produced by Shine.
Just weeks after announcing a fresh batch of promising Phase III data, the FDA has handed Genentech and its biotech partner Exelixis an approval to market cobimetinib in combination with Zelboraf among a genetically defined group of melanoma patients.
Researchers at UCLA's California NanoSystems Institute have developed a nanoparticle delivery system that improves an antibiotic's ability to combat the bacteria Francisella tularensis.
Johnson & Johnson's Janssen announced that a Phase IIb study of a combination regimen of two investigational long-acting injectable HIV drugs found that the therapy performed similarly to a regimen consisting of three oral medications.